Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
Recurrent cervical cancer has a grim prognosis with 5-year survival <5%. Current treatment options are limited; standards of care such as palliative chemotherapy and surgical resection often provide a small survival advantage. To date, only one targeted agent has FDA approval for the treatment of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2022-01-01
|
| Series: | Case Reports in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2022/6579715 |
| _version_ | 1798043875123658752 |
|---|---|
| author | Maya Gross Ryan J. Spencer |
| author_facet | Maya Gross Ryan J. Spencer |
| author_sort | Maya Gross |
| collection | DOAJ |
| description | Recurrent cervical cancer has a grim prognosis with 5-year survival <5%. Current treatment options are limited; standards of care such as palliative chemotherapy and surgical resection often provide a small survival advantage. To date, only one targeted agent has FDA approval for the treatment of recurrent cervical cancer. We present the case of a novel application of olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, as single-agent therapy for recurrent metastatic clear cell cervical cancer in a patient with a somatic BRCA2 mutation. The patient had excellent response to therapy with stable disease without evidence of progression until 14 months of therapy, at which time she was switched to an alternative regimen. |
| first_indexed | 2024-04-11T22:55:10Z |
| format | Article |
| id | doaj.art-352e57905e534b1f9373d985e7ab33db |
| institution | Directory Open Access Journal |
| issn | 2090-6692 |
| language | English |
| last_indexed | 2024-04-11T22:55:10Z |
| publishDate | 2022-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Case Reports in Obstetrics and Gynecology |
| spelling | doaj.art-352e57905e534b1f9373d985e7ab33db2022-12-22T03:58:27ZengHindawi LimitedCase Reports in Obstetrics and Gynecology2090-66922022-01-01202210.1155/2022/6579715Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, OlaparibMaya Gross0Ryan J. Spencer1Department of Obstetrics and GynecologyDivision of Gynecologic OncologyRecurrent cervical cancer has a grim prognosis with 5-year survival <5%. Current treatment options are limited; standards of care such as palliative chemotherapy and surgical resection often provide a small survival advantage. To date, only one targeted agent has FDA approval for the treatment of recurrent cervical cancer. We present the case of a novel application of olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, as single-agent therapy for recurrent metastatic clear cell cervical cancer in a patient with a somatic BRCA2 mutation. The patient had excellent response to therapy with stable disease without evidence of progression until 14 months of therapy, at which time she was switched to an alternative regimen.http://dx.doi.org/10.1155/2022/6579715 |
| spellingShingle | Maya Gross Ryan J. Spencer Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib Case Reports in Obstetrics and Gynecology |
| title | Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib |
| title_full | Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib |
| title_fullStr | Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib |
| title_full_unstemmed | Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib |
| title_short | Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib |
| title_sort | recurrent cervical cancer treated successfully with single agent parp inhibitor olaparib |
| url | http://dx.doi.org/10.1155/2022/6579715 |
| work_keys_str_mv | AT mayagross recurrentcervicalcancertreatedsuccessfullywithsingleagentparpinhibitorolaparib AT ryanjspencer recurrentcervicalcancertreatedsuccessfullywithsingleagentparpinhibitorolaparib |